Vyteris enlists LabCorp in national marketing agreement:
This article was originally published in Clinica
Vyteris, manufacturer of LidoSite (the first active drug delivery patch to receive US FDA marketing clearance) has sealed an agreement with Laboratory Corporation of America (LabCorp) to market the former's key product. The deal will make LabCorp the only US independent clinical laboratory offering LidoSite for outpatient use to physicians nationally, says Vyteris. The device is an iontophoresis-based product that uses low-level electrical energy to deliver drugs through the skin.